Jan 17 (Reuters) - Amgen Inc:
* FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLISÂ® (CARFILZOMIB) LABEL
* AMGEN INC - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS Source text for Eikon: Further company coverage:
 